Sunshine Biopharma, Inc. (SBFMW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
分析师预估 每股收益(EPS)为 $-4.12 和 营收为 $0.04B (下一财年).
每股收益(EPS)历史表现: 2024: 实际 $-7.32 vs 预期 $-4.12 (不及预期 -77.7%). 2025: 实际 $-1.44 vs 预期 $-1.01 (不及预期 -42.6%). 分析师准确度: 63%.
EPS 预测 — SBFMW
63%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$7.32
vs Est –$4.12
▼ 43.7% off
2025
Actual –$1.44
vs Est –$1.01
▼ 29.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
营收预测 — SBFMW
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.035B
vs Est $0.038B
▼ 8.4% off
2025
Actual $0.036B
vs Est $0.038B
▼ 3.9% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
